Enzon Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 11   

Articles published

ENZN 0.960 0.000 (0.00%)
price chart
Trending Stocks: Kindred Biosciences, Inc. (NASDAQ:KIN), Enzon ...
On last trading day Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) moved down -3.57% to close at $1.08. Its volatility for the week is 5.40% while volatility for the month is 8.15%.
Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer
CRANBURY, N.J., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Steve Carchedi as Chief ...
Related articles »  
NJ Tax Court Won't Revisit $3M Elan Assessment
Law360, New York (October 14, 2014, 7:34 PM ET) -- The Tax Court of New Jersey has denied Elan Pharmaceuticals Inc.'s request to reconsider the court's ruling that the pharmaceutical giant owes over $3 million in back state taxes connected to the sale ...
Trader's Watch List : Annaly Capital Management, Inc. (NYSE:NLY), ARMOUR ...
Mitcham Industries Inc. (NASDAQ:MIND) monthly performance is -16.03%. Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) has 4.95% insider ownership while its institutional ownership stands at 59.80%.
Related articles »  
Insiders Buy Large Volume: Uventus, Qualcomm and Middleburg
QUALCOMM INC/DE (QCOM) Executive JACOBS PAUL E initiated a Buy transaction dated Friday 19 September 2014 for 70,000 shares.
Related articles »  
Sigma-Tau, Alfa Wassermann in talks to combine Italian operations- sources
Sigma-Tau would retain control of its rare diseases business as well as its U.S. subsidiary, Sigma-Tau Pharmaceuticals Inc, which could then be sold separately in a deal worth over 1 billion euros (0.79 billion pounds), two of the sources said.
Related articles »  
Analyst Action on PTC Therapeutics, Team and Whiting Petroleum Corp.
The Wall Street Analysts Equities Firm Deutsche Bank Initiated coverage on PTC Therapeutics (PTCT). The Brokerage Firm had an action of 'Buy'.
Enzon Pharmaceuticals Inc Announces Auditor Change-Form 8-K
Enzon Pharmaceuticals Inc Announces $1.60 Special Dividend